AC
PTGX icon

Athanor Capital’s Protagonist Therapeutics PTGX Stock Holding History

Athanor Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,748
Closed -$227K – 687
2021
Q1 		$227K Sell
8,748
-6,778
-44% -$172K 0.01% 663
2020
Q4 		$313K Sell
15,526
-122
-0.8% -$2.63K 0.01% 569
2020
Q3 		$306K Buy
+15,648
New +$294K 0.01% 424

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Athanor Capital's PTGX Position: Q2 2021 in Review

Athanor Capital sold out of Protagonist Therapeutics (PTGX) in Q2 2021, closing a stake of 8,748 shares — an estimated $227K sold.

Athanor Capital first reported a position in PTGX in Q3 2020 and held it in 3 quarters. The position peaked at $313K in Q4 2020. 138 funds tracked by Wall St. Rank hold PTGX as of Q2 2021.

  • Athanor Capital reported no remaining Protagonist Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 8,748 Protagonist Therapeutics shares in Q2 2021, an estimated $227K.
  • Athanor Capital first reported a position in Protagonist Therapeutics in Q3 2020 and held it in 3 quarters.
  • Athanor Capital's Protagonist Therapeutics position peaked at $313K in Q4 2020.
  • 138 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.